Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

49.7K
Overview
49.7K
Leaky Scanning02:28

Leaky Scanning

5.5K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Afucosylated VAR2CSA-Specific IgG Reduces Risks of Placental Malaria.

The Journal of infectious diseases·2026
Same author

Respiratory virus genomic epidemiology during post-pandemic re-emergence of influenza in Australia.

Virus evolution·2026
Same author

Ecology of Low Pathogenicity Avian Influenza Virus H7 in Wild Birds in South-Eastern Australia Prior to Emergence of High Pathogenicity Avian Influenza H7 in Poultry.

Influenza and other respiratory viruses·2026
Same author

Surveillance of Migratory Shorebirds and Seabirds in 2024 in Australia Reveals Incursions of a Diversity of Low Pathogenicity Avian Influenza Viruses, but Not High Pathogenicity Avian Influenza H5N1.

Influenza and other respiratory viruses·2026
Same author

Using an RNA binding protein to detect mRNA on lipid nanoparticles.

Scientific reports·2026
Same author

Influenza vaccine responses differ between young children previously exposed to influenza antigens via infection versus vaccination.

Communications medicine·2026

Related Experiment Video

Updated: Dec 1, 2025

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

13.0K

New Technologies for Influenza Vaccines.

Steven Rockman1,2, Karen L Laurie1, Simone Parkes1

  • 1Technical Development, Seqirus Ltd, Parkville, Victoria 3052, Australia.

Microorganisms
|November 11, 2020
PubMed
Summary

Next-generation influenza vaccines leverage existing technologies for faster development. Innovations in manufacturing, design, and platforms promise improved vaccine options beyond traditional methods.

Keywords:
cell-based influenza vaccinescell-cultureegg-based influenza vaccinesinfluenzamRNA vaccinesrecombinant vaccinesuniversal vaccinevaccine

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.5K
Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System
12:18

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

24.6K

Related Experiment Videos

Last Updated: Dec 1, 2025

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

13.0K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.5K
Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System
12:18

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

24.6K

Area of Science:

  • Vaccinology
  • Infectious Disease Research
  • Biotechnology

Background:

  • Traditional vaccine development is lengthy and costly.
  • The SARS-CoV-2 pandemic accelerated vaccine research, highlighting existing technology's role.
  • Influenza vaccine development has benefited from these advancements.

Purpose of the Study:

  • To review next-generation, non-egg-based influenza vaccine technologies.
  • To discuss advancements in manufacturing, antigen design, and novel platforms.
  • To provide an update on universal influenza vaccine efforts.

Main Methods:

  • Review of emerging vaccine technologies.
  • Analysis of structure-based antigen design and computational biology.
  • Exploration of recombinant protein, nanoparticle, gene-, and vector-based platforms.

Main Results:

  • Significant progress in non-egg-based influenza vaccine development.
  • Leveraging existing technologies has expedited vaccine creation.
  • Multiple promising platforms are advancing rapidly.

Conclusions:

  • Next-generation influenza vaccines offer faster and potentially more effective alternatives.
  • Technological innovation is key to overcoming traditional vaccine development hurdles.
  • Continued research into universal influenza vaccines is ongoing.